Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | KDM5A | P29375 | 6/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092524 | 0.93 | KDM5A (0.39) | ADORA2BADORA2AADORA1KDM5AKDM5B | |
| SCHEMBL16092324 | 0.90 | CREBBP (0.44) | ADORA2BADORA2AADORA1KDM5AKDM5B | |
| SCHEMBL16092494 | 0.89 | ADORA2B (0.48) | ADORA2BADORA2AADORA1KDM5BALK | |
| SCHEMBL16092484 | 0.87 | ADORA2B (0.45) | ADORA2BADORA2AADORA1KDM5AKDM5B | |
| SCHEMBL16092313 | 0.86 | KDM5B (0.50) | ADORA2BADORA2AADORA1KDM5AKDM5B | |
| SCHEMBL16092356 | 0.86 | KDM5B (0.46) | ADORA2BADORA2AADORA1KDM5AKDM5B | |
| SCHEMBL17547793 | 0.85 | KDM5B (0.51) | ADORA2BADORA2AADORA1KDM5AKDM5B | |
| SCHEMBL17547800 | 0.85 | KDM5B (0.44) | ADORA2BADORA2AADORA1KDM5AKDM5B | |
| SCHEMBL16092509 | 0.85 | KDM5A (0.38) | KDM5AKDM5BKDM5C | |
| SCHEMBL17547803 | 0.85 | RET (0.43) | ADORA2BADORA2AADORA1KDM5AKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | ADORA2B 3759/4885ADORA2A 3367/4885ADORA1 3600/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | ADORA2B 3759/4885ADORA2A 3367/4885ADORA1 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.